Varonis Systems (NASDAQ:VRNS) Sets New 1-Year Low – Here’s What Happened

Varonis Systems, Inc. (NASDAQ:VRNS) reached a new 52-week low on Friday . The company traded as low as $29.75 and last traded at $29.84, with a volume of 3228177 shares changing hands. The stock had previously closed at $30.57.

Varonis Systems News Roundup

Here are the key news stories impacting Varonis Systems this week:

• Negative Sentiment: Frank R. Cruz law firm says Varonis shareholders who lost money can seek lead‑plaintiff status in a securities fraud suit alleging misstatements about the SaaS transition. Read More.
• Negative Sentiment: Hagens Berman issued an investor alert highlighting a securities class action that accuses Varonis of misleading the market on its ability to convert on‑prem customers to SaaS; the firm reminds investors of the March 9, 2026 lead‑plaintiff deadline. Read More.
• Negative Sentiment: Bronstein, Gewirtz & Grossman announces a class action filed against Varonis and certain officers seeking recovery for investors who bought shares during the alleged misstatement period (Feb 4–Oct 28, 2025). Read More.
• Negative Sentiment: Kessler Topaz issued a shareholder reminder about the securities‑fraud class action and the class period (Feb 4–Oct 28, 2025), encouraging claims before the deadline. Read More.
• Negative Sentiment: Levi & Korsinsky notifies shareholders of the class action and urges affected investors to inquire about joining the case—another sign of multiple firms pursuing similar claims. Read More.
• Negative Sentiment: Bragar Eagel & Squire reminds investors of the March 9 lead‑plaintiff deadline and solicits contacts from those who experienced losses during the alleged class period. Read More.
• Negative Sentiment: Rosen Law Firm and Pomerantz (separate notices) also alert investors about the class action and deadlines—reinforcing that many firms expect damages claims tied to the SaaS transition messaging. Read More. Read More.
• Negative Sentiment: The Gross Law Firm and Faruqi & Faruqi issued investor notices investigating potential claims and encouraging affected shareholders to seek lead‑plaintiff status—adding to legal cost and distraction risk. Read More. Read More.
• Negative Sentiment: Robbins Geller and Bernstein Liebhard also announced opportunities for lead‑plaintiff applications and investigations, signaling widespread plaintiff‑firm interest that typically increases settlement leverage against companies. Read More. Read More.
• Negative Sentiment: Seeking Alpha commentary argues Varonis is being outpaced by larger rivals as cloud/SaaS trends benefit giants — a narrative that can weigh on sentiment beyond the litigation headlines. Read More.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on VRNS shares. Royal Bank Of Canada lowered their price objective on Varonis Systems from $60.00 to $41.00 and set an “outperform” rating for the company in a research report on Monday, January 5th. Piper Sandler raised shares of Varonis Systems from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $45.00 to $47.00 in a research note on Monday, January 5th. UBS Group set a $50.00 price target on shares of Varonis Systems in a report on Monday, January 26th. Truist Financial reissued a “buy” rating and issued a $50.00 price target (down previously from $70.00) on shares of Varonis Systems in a report on Wednesday, October 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Varonis Systems in a research report on Wednesday, January 21st. Fifteen research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $53.50.

Varonis Systems Trading Down 2.4%

The company has a debt-to-equity ratio of 0.75, a current ratio of 1.81 and a quick ratio of 1.81. The stock’s 50 day moving average is $33.16 and its 200-day moving average is $46.12. The company has a market capitalization of $3.52 billion, a P/E ratio of -29.25 and a beta of 0.56.

Hedge Funds Weigh In On Varonis Systems

Several institutional investors and hedge funds have recently added to or reduced their stakes in VRNS. Bessemer Group Inc. grew its position in shares of Varonis Systems by 179.1% in the 2nd quarter. Bessemer Group Inc. now owns 494 shares of the technology company’s stock worth $25,000 after buying an additional 317 shares during the period. Allworth Financial LP boosted its stake in Varonis Systems by 201.3% during the third quarter. Allworth Financial LP now owns 693 shares of the technology company’s stock worth $40,000 after acquiring an additional 463 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in Varonis Systems in the third quarter worth about $42,000. First Horizon Corp bought a new position in shares of Varonis Systems during the third quarter valued at approximately $45,000. Finally, Westside Investment Management Inc. lifted its holdings in shares of Varonis Systems by 100.0% during the third quarter. Westside Investment Management Inc. now owns 844 shares of the technology company’s stock valued at $49,000 after purchasing an additional 422 shares during the last quarter. Hedge funds and other institutional investors own 95.65% of the company’s stock.

Varonis Systems Company Profile

Varonis Systems is a cybersecurity firm specializing in the protection and management of unstructured data. The company’s flagship Data Security Platform provides advanced analytics for monitoring file systems, email servers, collaboration platforms and cloud storage. By continuously mapping and analyzing data permissions and user behavior, Varonis enables organizations to detect insider threats, verify compliance and remediate exposed data in real time.

Founded in 2005 and headquartered in New York City, Varonis serves a diverse global customer base across financial services, healthcare, media, manufacturing and government.